Literature DB >> 16212578

Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora.

Clay Walker1, Philip M Preshaw, John Novak, Arthur F Hefti, Mark Bradshaw, Christopher Powala.   

Abstract

AIM: The purpose of this study was to determine if a 9-month regimen of sub-antimicrobial doxycycline (20 mg, bid) had an effect on either the intestinal or the vaginal microflora.
MATERIAL AND METHODS: A total of 69 periodontally diseased subjects were randomized to receive drug or placebo control for a 9-month period. Stool specimens and vaginal swabs were collected at baseline and after 3 and 9 months of therapy. Samples were examined for total anaerobic counts, opportunistic pathogens, and doxycycline-resistant (>or=4 microg/ml) bacteria. All isolates that survived sub-culture were identified and their susceptibilities determined to six antibiotics. Analyses were performed to determine if treatment differences were present.
RESULTS: The only statistically significant differences (p<0.05) between the two treatment groups occurred in the doxycycline-resistant counts at the baseline sample period for the faecal samples. This imbalance was before treatment initiation and the administration of the study drug. No between-treatment differences were detected at either the 3- or 9-month sample period either in the predominant bacterial taxa present or in their antibiotic susceptibilities.
CONCLUSIONS: There was no evidence that sub-antimicrobial doxycycline treatment exerted an effect on the composition or doxycycline resistance level of either the faecal or the vaginal microflora. Copyright (c) Blackwell Munksgaard, 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212578     DOI: 10.1111/j.1600-051X.2005.00840.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  18 in total

1.  Metalloproteases and tendinopathy.

Authors:  Angelo Del Buono; Francesco Oliva; Leonardo Osti; Nicola Maffulli
Journal:  Muscles Ligaments Tendons J       Date:  2013-05-21

2.  Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.

Authors:  Jay-Hyun Jo; Catriona P Harkins; Nicole H Schwardt; Jessica A Portillo; Matthew D Zimmerman; Claire L Carter; Md Amir Hossen; Cody J Peer; Eric C Polley; Véronique Dartois; William D Figg; Niki M Moutsopoulos; Julia A Segre; Heidi H Kong
Journal:  Sci Transl Med       Date:  2021-12-22       Impact factor: 17.956

Review 3.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

4.  Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results.

Authors:  Clay Walker; Susan Puumala; Lorne M Golub; Julie A Stoner; Richard A Reinhardt; Hsi-Ming Lee; Jeffrey B Payne
Journal:  J Periodontol       Date:  2007-08       Impact factor: 6.993

Review 5.  Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.

Authors:  Björn Pasternak; Per Aspenberg
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

6.  The effect of doxycycline on canine hip osteoarthritis: design of a 6-months clinical trial.

Authors:  Korakot Nganvongpanit; Peraphan Pothacharoen; Niyada Suwankong; Siriwan Ong-Chai; Prachya Kongtawelert
Journal:  J Vet Sci       Date:  2009-09       Impact factor: 1.672

7.  Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine.

Authors:  Ying Gu; Clay Walker; Maria E Ryan; Jeffrey B Payne; Lorne M Golub
Journal:  J Oral Microbiol       Date:  2012-10-12       Impact factor: 5.474

Review 8.  Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases.

Authors:  Lorne M Golub; Muna S Elburki; Clay Walker; Maria Ryan; Timo Sorsa; Howard Tenenbaum; Michael Goldberg; Mark Wolff; Ying Gu
Journal:  Int Dent J       Date:  2016-03-23       Impact factor: 2.607

9.  Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves' Orbitopathy.

Authors:  Miaoli Lin; Yuxiang Mao; Siming Ai; Guangming Liu; Jian Zhang; Jianhua Yan; Huasheng Yang; Aimin Li; Yusha Zou; Dan Liang
Journal:  Int J Endocrinol       Date:  2015-06-29       Impact factor: 3.257

10.  A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.

Authors:  Abdelwahed Chtarto; Marie Humbert-Claude; Olivier Bockstael; Atze T Das; Sébastien Boutry; Ludivine S Breger; Bep Klaver; Catherine Melas; Pedro Barroso-Chinea; Tomas Gonzalez-Hernandez; Robert N Muller; Olivier DeWitte; Marc Levivier; Cecilia Lundberg; Ben Berkhout; Liliane Tenenbaum
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.